Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5209321
Max Phase: Preclinical
Molecular Formula: C21H20FN3O
Molecular Weight: 349.41
Associated Items:
ID: ALA5209321
Max Phase: Preclinical
Molecular Formula: C21H20FN3O
Molecular Weight: 349.41
Associated Items:
Canonical SMILES: CCc1ccc2c(c1)nc(NCc1ccco1)n2Cc1ccc(F)cc1
Standard InChI: InChI=1S/C21H20FN3O/c1-2-15-7-10-20-19(12-15)24-21(23-13-18-4-3-11-26-18)25(20)14-16-5-8-17(22)9-6-16/h3-12H,2,13-14H2,1H3,(H,23,24)
Standard InChI Key: GIMLTJKTWJKZGR-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 349.41 | Molecular Weight (Monoisotopic): 349.1590 | AlogP: 4.99 | #Rotatable Bonds: 6 |
Polar Surface Area: 42.99 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 6.81 | CX LogP: 5.25 | CX LogD: 5.16 |
Aromatic Rings: 4 | Heavy Atoms: 26 | QED Weighted: 0.53 | Np Likeness Score: -1.85 |
1. Chen L, Zhang Z, Tian H, Jiang S, Ji Y, Liu M, Shen J, Cao Z, Wang K.. (2022) Synthesis of AC1903 analogs as potent transient receptor potential canonical channel 4/5 inhibitors and biological evaluation., 68 [PMID:35653869] [10.1016/j.bmc.2022.116853] |
Source(1):